Bone Mineral Density

Fracture and mortality risks for men aged 80 years or older have different profiles, and an assessment of both could help to inform osteoporosis drug treatment decisions, according to a speaker.

A menarche-centered model assessing age at peak bone mineral density suggests bone loss women may begin as soon as 5 years after menarche, even among athletes, according to an analysis of longitudinal data.

HIV and menopausal stage are both independent predictors of lower bone mineral density in women, particularly in the lumbar spine and hip, according to a study published in Clinical Infectious Diseases.

Postmenopausal women with low bone mass saw greater gains in spine bone mineral density and less bone turnover when assigned monthly risedronate therapy compared with a 12-month regimen of impact and resistance exercises, study data show.

People with diabetes and less appendicular skeletal muscle mass are more likely to have lower bone mineral density in the lumbar spine, hip and femoral neck and are at a greater risk for osteoporosis, according to study data.

A recent study demonstrated that lower fat intake and higher fiber and vitamin C intake led to a lower long-term risk for CVD in adults newly diagnosed with type 2 diabetes. It was the top story in endocrinology last week.

Boys who engaged in high-impact exercise in early adolescence experienced greater gains in bone mineral density compared with boys who reported no exercise practice, data from a population-based study show.

Among adults with differentiated thyroid cancer on thyroid-stimulating hormone suppression therapy, postmenopausal women had lower bone mineral density at the lumbar spine whereas premenopausal women had greater BMD vs. healthy controls.

Data showed that 1 year of romosozumab followed by a year of alendronate was associated with larger gains in bone mineral density at the lumbar spine than 2 years of alendronate alone in postmenopausal women with osteoporosis.

Postmenopausal women with osteoporosis receiving romosozumab for 12 months had larger improvements in bone mineral density and bone strength at the lumbar spine compared with those receiving alendronate alone, according to study data.